

SEPTEMBER  
23-27<sup>TH</sup>  
2024



BRAZILIAN MEETING  
ON ORGANIC SYNTHESIS  
BENTO GONÇALVES, RS - BRAZIL

## Selenium dioxide in the synthesis of oxazole-5-carbaldehydes

Gabriela T. de Quadros<sup>1\*</sup>, Loana I. Monzon<sup>1</sup>, Laura Abenante<sup>2</sup>, and Eder J. Lenardão<sup>1</sup>

1) Centro de Ciências Químicas, Farmacêuticas e de Alimentos, CCQFA. Federal University of Pelotas, UFPEL, CEP 96010-900, Pelotas, RS, Brazil.

2) Instituto de Biotecnologia, University of Caxias do Sul, UCS, CEP 95070-560, Caxias do Sul, RS, Brazil.

\*e-mail: [gabrielatrischdequadros@gmail.com](mailto:gabrielatrischdequadros@gmail.com)

Keywords: oxazole, selenium dioxide, propargylamide.

### ABSTRACT

Heterocyclic systems are a prominent class of compounds, which are widely found in nature and extensively applied in different industrial segments.<sup>1</sup> Among them, oxazole derivatives are a class of biologically privileged structures, which play an important role in the prospection of new drugs in the pharmaceutical industry, being the core of important bioactive molecules.<sup>2</sup> Among the pharmacological properties of oxazoles are antitubercular,<sup>3</sup> anticancer,<sup>4</sup> antibacterial,<sup>5</sup> antifungal,<sup>6</sup> and antidiabetic.<sup>7</sup>

In this work it was developed a simple and efficient methodology to access 2-substituted oxazole-5-carbaldehydes. In this strategy, intramolecular cyclization reactions of *N*-propargylamide **1a-i** were performed, using selenium dioxide (1.5 equiv.) as the oxidant and acetonitrile as a solvent. The reactions were conducted at 80 °C for 4 h, leading to the respective oxazoles **2a-i** in good to excellent yields (Scheme 1).



Scheme 1. Synthesis of 2-substituted oxazole-5-carbaldehydes.

### ACKNOWLEDGEMENTS

We thank the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) – Finance Code 001. FAPERGS, CNPq and FINEP for financial support.

### REFERENCES

1. a) L. D. Quin, J. A. Tyrell, in *Fundamentals of Heterocyclic Chemistry*, Wiley-VCH, Weinheim, **2010**; b) f) A. Gomtsyan, *Chem. Heterocycl. Compd.* **2012**, *48*, 7–10. 2. E. Vitaku, D. T. Smith, J. T. Njardarson, *J. Med. Chem.* **2014**, *57*, 10257–10274; b) R. Vardanyan, V. Hruby, in *Synthesis of Best-Seller Drugs*, Academic Press: London, **2016**. 3. Y. K. Abhale, A. V. Sasane, A. P. Chavan, S. H. Shekh, K. K. Deshmukh, S. Bhansali, L. Nawale, D. Sarkar, P. C. Mhaske, *Eur. J. Med. Chem.* **2017**, *132*, 333–340. 4. R. Maini, L. M. Dedkova, R. Paul, M. M. Madathil, S. R. Chowdhury, S. Chen, S. M. Hecht, *J. Am. Chem. Soc.* **2015**, *137*, 11206–11209. 5. N. Li, Y. Xu, Q. Xia, C. Bai, T. Wang, L. Wang, D. He, N. Xie, L. Li, J. Wang, H.-G. Zhou, F. Xu, C. Yang, Q. Zhang, Z. Yin, Y. Guo, Y. Chen, *Bioorg. Med. Chem. Lett.* **2014**, *24*, 386–389. 6. M.-Z. Zhang, C.-Y. Jia, Y.-C. Gu, N. Mulholland, S. Turner, D. Beattie, W.-H. Zhang, G.-F. Yang, J. Clough, *Eur. J. Med. Chem.* **2017**, *126*, 669–674. 7. I. Zahanich, I. Kondratov, V. Naumchyk, Y. Kheylik, M. Platonov, S. Zozulya, M. Krasavin, *Bioorg. Med. Chem. Lett.* **2015**, *25*, 3105–3111.